REVVITY INC. DL 1/ US7140461093 /
| 2024-04-26 8:08:32 AM | Chg. -0.32 | Volume | Bid7:27:55 PM | Ask7:27:55 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 94.90EUR | -0.34% | 0 Turnover: 0.00 |
95.86Bid Size: 320 | 96.20Ask Size: 320 | 11.81 bill.EUR | - | - |
GlobeNewswire
01-19
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
01-08
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
2023-11-30
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
2023-11-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
2023-11-05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
2021-05-18
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
2021-05-11
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
2021-04-29
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...
